



ABSTRACT OF THE DISCLOSURE

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula:




wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas:




- where q is 1, 2, or 3, W^3 is $-O-$; $-N(R^9)-$; or $-OC(=O)-$; R^7 is selected from $-H$; $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl, or $-(C_2-C_6)$ alkynyl substituted by 0 to 3 substituents R^{10} ; $-(CH_2)_u-(C_3-C_7)$ cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R^{10} ; and phenyl or benzyl substituted by 0 to 3 R^{14} ; R^8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[*b*]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2*H*-1-benzopyranyl; 2-*H*-chromenyl; chromanyl; benzothienyl; 1*H*-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyll; isoquinolinyll; quinazolinyll; quinoxalinyll; pyrazolo[3,4-*d*]pyrimidinyl; pyrimido[4,5-*d*]pyrimidinyl; imidazo[1,2-*a*]pyridinyl; pyridopyridinyl; pteridinyl; or 1*H*-purinyl; or A is selected from phosphorous and sulfur acid groups; W is $-O-$; $-S(=O)_t-$, where t is 0, 1, or 2; or $-N(R^3)-$; Y is $=C(R^1)_a-$, or


- 5 -[N \Rightarrow (O)]_k] where k is 0 or 1; R⁴, R⁵ and R⁶ are (1) -H; provided that R⁵ and R⁶ are not both -H at the same time, -F; -Cl; -(C₂-C₄) alkynyl; -R¹⁶; -OR¹⁶; -S(=O)_pR¹⁶; -C(=O)R¹⁶; -C(=O)OR¹⁶; -OC(=O)R¹⁶; -CN; -NO₂; -C(=O)NR¹⁶R¹⁷; -OC(=O)NR¹⁶R¹⁷; -NR¹²_aC(=O)NR¹⁶R¹⁷; -NR¹²_aC(=NR¹²)NR¹⁶R¹⁷; -NR¹²_aC(=NCN)NR¹⁵R¹⁶; -NR¹²_aC(=N-NO₂)NR¹⁵R¹⁶; -C(=NR¹²_a)NR¹⁵R¹⁶; -CH₂C(=NR¹²_a)NR¹⁶R¹⁷; -OC(=NR¹²_a)NR¹⁶R¹⁷; -OC(=N-NO₂)NR¹⁶R¹⁷; -NR¹⁶R¹⁷; -CH₂NR¹⁶R¹⁷; -NR¹²_aC(=O)R¹⁶; -NR¹²_aC(=O)OR¹⁶; =NOR¹⁶; -NR¹²_aS(=O)_pR¹⁷; -S(=O)_pNR¹⁶R¹⁷; and -CH₂C(=NR¹²_a)NR¹⁶R¹⁷; (2) -(C₁-C₄) alkyl including dimethyl and -(C₁-C₄) alkoxy substituted with 0 to 3 substituents -F or -Cl; or 0 or 1 substituent (C₁-C₂) alkoxycarbonyl-, (C₁-C₂) alkylcarbonyl-, or (C₁-C₂) alkylcarbonyloxy-; or (3) an aryl or heterocyclic moiety; or (4) R⁵ and R⁶ are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15):




(1.3.1)




(1.3.2)




(1.3.3)




(1.3.4)




(1.3.5)




(1.3.6)




(1.3.7)




(1.3.8)




(1.3.9)




(1.3.10)




(1.3.11)




(1.3.12)



(1.3.13)



(1.3.14)



(1.3.15)

or a pharmaceutically acceptable salt thereof.